Gem/nab-PTX
Phase 1Small molecule
Gem/nab-PTX is one of 90 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Cyclophosphamid
EEssen Biotech
Preclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gem/nab-PTX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSONIRE Therapeutics Inc.